ea0037gp.28.04 | Endocrine tumours and neoplasia – NETS | ECE2015
Gagliano Tersa
, Benfini Katiusci
, Gentilin Erica
, Falletta Simona
, Bondanelli Marta
, Di Pasquale Carmelina
, Riva Eleonora
, degli Ubertu Ettore
, Zatelli Maria Chiara
Surgery is not feasible for infiltrating and metastatic bronchopulmonary NET (BP-NET). In those cases, medical therapy is tried with controversial results. Thus, it is important to identify new therapeutic targets to provide adequate medical treatment for patients with BP-NET. Sunitinib, is a multi-targeted receptor tyrosine kinase inhibitor (TKI), mainly described to inhibit VEGFR.The aim of our study is to verify whether insulin receptor (IR), IGF1R, a...